Fundz

Inovio

Plymouth Meeting, Pennsylvania, United States · Biotechnology

INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. Our mission: deliver on the promise of DNA medicine for patients around the world.

Key facts

Headquarters
Plymouth Meeting, Pennsylvania, United States
Employees
140
Industries
Biotechnology
Status
Public (INO)
Website
inovio.com
LinkedIn
Company page

Recent activity at Inovio

  • : SEC 8-K (1.01):
  • : SEC 8-K (8.01): On October 30, 2026, Inovio Pharmaceuticals, Inc. announced that the FDA granted accelerated approval for VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), aimed at reducing the frequency of surgery for adults with Recurrent Respiratory Papillomatosis (RRP). This approval is based on the demonstration of a complete response, with no need for surgical intervention in the 12 months following treatment. The company is required to conduct a confirmatory study to verify the clinical benefits, with protocol drafts due by the end of 2026. VOCERYQ is expected to be available for order in about 60 days, with full rollout anticipated in Q1 2027.
  • : SEC 8-K (5.03): On October 6, 2026, the Board of Directors of Inovio Pharmaceuticals, Inc. approved an amendment to the Company's Bylaws, which introduces a new Article 12 (Exclusive Forum). This amendment stipulates that, unless the Company agrees otherwise in writing, the Court of Chancery of the State of Delaware will serve as the exclusive forum for certain legal actions, including derivative actions and claims against directors and officers for breaches of fiduciary duty. This change is effective immediately and is significant as it impacts where legal disputes can be resolved, potentially limiting the options for shareholders and impacting future legal strategies.
  • : SEC 8-K (1.01): On July 29, 2026, Inovio Pharmaceuticals, Inc. entered into an underwriting agreement with Piper Sandler & Co. for the public offering of 21,052,632 shares of its common stock and accompanying warrants. The offering price is set at $0.95 per share, with the exercise price for the warrants at $1.10 per share. The underwriter was granted a 30-day option to purchase additional shares and warrants; this option was exercised on July 29, 2026, for additional warrants. The company expects to net approximately $18.3 million from this offering, which is set to close on or about July 31, 2026, pending customary closing conditions.
  • : INOVIO Partners with ApolloBio to Submit Regulatory Filing for VGX-3100 Following Successful Phase 3 Trial.
  • : SEC 8-K (1.01):
  • : SEC 8-K (8.01): On April 1, 2026, Inovio Pharmaceuticals, Inc. notified Oppenheimer & Co. Inc. that it was suspending and terminating the ATM Prospectus related to the Sales Agreement established on August 13, 2024. This decision halts the sale of common stock under the existing agreement until a new prospectus is filed. To date, the Company has sold 1,319,644 shares of its common stock for gross proceeds of $3.2 million under this program. The Sales Agreement remains effective, which signifies that the Company retains the option to resume sales in the future if a new prospectus is submitted.
  • : SEC 8-K (1.01): On January 27, 2026, Inovio Pharmaceuticals, Inc. amended its outstanding Series A warrants issued on July 7, 2025, to extend their expiration date to March 31, 2026. The Series A Warrants, which enable the purchase of up to 13,564,268 shares of common stock at an exercise price of $1.75 per share, would have otherwise expired on January 28, 2026. This amendment is significant as it provides additional time for warrant holders to exercise their options in light of the acceptance of a Biologics License Application for INO-3107 by the FDA. All other terms of the warrants remain unchanged, and this amendment will also be documented in a prospectus supplement filed with the SEC.
  • : SEC 8-K (7.01): On December 29, 2025, Inovio Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologic License Application (BLA) for INO-3107, which is an investigational immunotherapy aimed at treating recurrent respiratory papillomatosis (RRP) in adults. This acceptance marks a significant milestone for the company, as it could lead to advancements in treatment options for the condition. The announcement was made through a press release, which is attached as Exhibit 99.1 to the filing. This development has strategic implications for Inovio's positioning in the immunotherapy market.
  • : SEC 8-K (8.01): On December 29, 2025, Inovio Pharmaceuticals, Inc. announced that the U.S. FDA has accepted its Biologic License Application (BLA) for INO-3107, an investigational immunotherapy targeting recurrent respiratory papillomatosis (RRP) in adults. The FDA has designated the review classification as Standard and set a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026, indicating when action on the application is expected. Notably, the FDA raised concerns about the adequacy of the company's information justifying eligibility for the accelerated approval pathway under which the BLA was filed. As a response, Inovio plans to request a meeting with the FDA to discuss the next steps for maintaining eligibility under the accelerated approval program, as they are not pursuing the traditional approval pathway for this drug.

Inovio funding history

DateRoundAmount
Jan 2020Seed$4.0M
Aug 2019Venture$15.2M

Leadership

  • Lota Zoth, Director
  • Wendy Yarno, Director
  • David Weiner, Director
  • Ann Miller, Director
  • Morton Collins, Director
  • Angel Cabrera, Director
  • Simon Benito, Director
  • J. Kim, Executive Officer, Director
  • Jacqueline Shea, President
  • Steven Egge, Chief Commercial Officer
  • Laurent Humeau, Executive Officer

Verified email and direct lines for Inovio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Inovio in the news

Companies similar to Inovio

About Inovio: questions and answers

What does Inovio do?

INOVIO is a clinical stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. Our mission: deliver on the promise of DNA medicine for patients around the world.

Where is Inovio headquartered?

Inovio is headquartered in Plymouth Meeting, Pennsylvania, United States.

How many employees does Inovio have?

Inovio has about 140 employees.

Has Inovio raised funding?

Yes. Fundz has recorded 2 funding events for Inovio. The most recent, Seed of $4.0M, was in Jan 2020.

Who leads Inovio?

Jacqueline Shea is a President at Inovio.

What is the latest news on Inovio?

On Nov 09, 2026, SEC 8-K (1.01):

Is Inovio a public company?

Yes. Inovio is publicly traded under the ticker INO.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Inovio across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.